NCT05828225View on ClinicalTrials.gov

Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

April 20, 2026

Study Completion Date

April 20, 2026

Conditions
Myasthenia Gravis
Interventions
DRUG

CD19 CAR-T cells injection

CD19 CAR-T in the Treatment of Refractory Myasthenia Gravis

Trial Locations (1)

310000

RECRUITING

The first affiliated hospital of medical college of zhejiang university, Hangzhou

All Listed Sponsors
lead

Zhejiang University

OTHER